Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - DOCTORS IN LEAGUE WITH WALL STREET ANALYSTS

US committee probes doctors’ complicity with Wall Street analysts

 

BY OUR PHARMA  CORRESPONDENT

11 August, 2005: Following reports in a national daily, the US Senate finance committee has called for a federal investigation into claims that some doctors are supplying Wall Street analysts with crucial and confidential clinical trials information before the public announcements of results.

A report in the Seattle Times cited 26 cases in which doctors had allegedly leaked details of their research to investment firms, despite having signed strict confidentiality agreements.

The article, entitled Selling Drug Secrets, reported that some of Wall Street's largest and most influential brokerage firms and hedge funds tried to obtain trial data on potential new drugs by paying doctors close to the research to reveal their thoughts on upcoming pipeline treatments.

With a single drug's prospects often determining whether a small biotech company's share price soars or crashes, inside information can prove invaluable to investors looking to exploit quick price swings by buying stock low or selling it high.

Senators had asked the Department of Justice and the Securities and Exchange Commission (SEC) to conduct a `complete and thorough review' of the allegations.

The article also claimed that hedge funds and mutual funds pay up to $1m a year to `matchmaker' firms, which pair Wall Street investment firms with doctors involved in ongoing clinical trials. It reported that the largest of these firms, Gerson Lehrman, has contractual agreements with more than 60,000 doctors to speak to investors.

Gerson Lehrman reacted to the claims by publishing a statement, making clear that the company allowed investors to avoid companies that “excel in marketing more than medicine”.

The Pharmaceutical Research and Manufacturers of America (PhRMA), the body representing the US pharma industry, condemned the practice of providing investors with inside information about clinical drug trials.

“If a doctor breaks securities laws or his or her confidentiality agreement with a pharmaceutical research company to gain financially, they should be severely punished,” a PhRMA spokesperson said.

Senators asked the Department of Justice and the SEC whether Congress should consider tightening legislation on divulging medical information to investors. The agencies are yet to comment on the allegations.

BY OUR PHARMA  CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us